Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZYDPLA1 in Healthy Volunteers
NCT02620592Phase 1Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ZYDPLA1 with Placebo (2 arms). Primary endpoint: Safety and tolerability assessed by monitoring adverse events, clinical, laboratory, electrocardiogram, and vital signs examinations at 28 Days. Started Oct 2014; status: completed.
02
Drugs
ZYDPLA1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02620592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620592.